Immunovaccine is a clinical-stage vaccine development company focused on the advancement of its patented DepoVax vaccine adjuvanting platform and product candidates for cancer therapy, infectious disease and animal health. Demonstrating safety and immunogenicity potential, Immunovaccine has advanced its platform technology and proprietary cancer vaccines into Phase I human clinical trials. The company is also advancing a broad infectious disease pipeline that includes vaccines for malaria, RSV and anthrax, and a collaborative anti-cocaine vaccine program. For more information, visit the company’s Web site at www.imvaccine.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: